Clinical Trial Update: Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial [Phase 2]

View source ↗

Summary

This is a Phase IIa, single-arm clinical trial evaluating a triple combination of iparomlimab, tuvonralimab, and nimotuzumab for recurrent or metastatic nasopha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma | Phase 2 | Status: RECRUITING